Sanofi ends development of Nurix-partnered STAT6 immune drug

· Health · France · United States

Sanofi is stopping development of SAR448272, an experimental immune drug partnered with Nurix Therapeutics that targets STAT6, a protein many analysts see as a potential pillar of the next generation of immunology medicine, Endpoints News and BioPharma Dive reported. The decision sparked a sell-off in Nurix shares and analyst debate about the prospects of drugs designed to degrade the hard-to-reach protein. The setback casts doubt on a closely watched class of targeted protein degraders in immunology.

Why it matters：The halt tests confidence in STAT6 degraders as a new immunology platform and will shape how partners value similar programs.

Key points

  • SAR448272 targeted STAT6, a protein regarded as key to next-generation immunology
  • Nurix shares fell on the news
  • Analysts are debating prospects for the degrader class

Sources (original reporting)

More stories from this day